IL10 and B-cell chronic lymphocytic leukemia: These results suggest ibrutinib blocks early induction (within 4 h) of IL10 mRNA by a TLR-agonist in CLL cells while ruxolitinib blocks late transcription (at 24 h) by inhibiting JAK-activity.